# Z-rostudirsen PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/z-rostudirsen

> The PDUFA target action date for z-rostudirsen, sponsored by Dyne Therapeutics, Inc. (DYN), is January 21, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the z-rostudirsen PDUFA date?

The PDUFA target action date for z-rostudirsen, sponsored by Dyne Therapeutics, Inc. (DYN), is January 21, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -" Last confirmed November 5, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/z-rostudirsen)

Source: Press release filed with the SEC (EX-99), accession 0001818794-26-000013, https://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/z-rostudirsen#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | z-rostudirsen |
| Codes | DYNE-251 |
| Sponsor | Dyne Therapeutics, Inc. (DYN) https://sec-api.dev/companies/dyn/catalysts |
| Indications | individuals with dmd amenable to exon 51 skipping |
| Modality | antisense |
| FDA designations | accelerated, breakthrough, fast track, orphan, priority review |

## Timeline

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-12-08, last confirmed 2026-05-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-215720): "Dyne plans to initiate a global confirmatory Phase 3 clinical trial of z-rostudirsen in Q2 2026." https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/dyn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-084207): "Dyne remains on track to initiate a global confirmatory Phase 3 clinical trial of z-rostudirsen in Q2 2026." https://www.sec.gov/Archives/edgar/data/1818794/000119312526084207/dyn-ex99_1.htm
- SEC Form 8-K (accession 0001193125-25-310516): "The Company plans to initiate a global Phase 3 clinical trial of z-rostudirsen in the second quarter of 2026 to support global approvals." https://www.sec.gov/Archives/edgar/data/1818794/000119312525310516/d16518d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-310516): "Dyne plans to initiate a global Phase 3 clinical trial of z-rostudirsen in Q2 2026 to support global approvals." https://www.sec.gov/Archives/edgar/data/1818794/000119312525310516/d16518dex991.htm
- SEC Form 10-Q (accession 0001193125-26-215702): "Further, we plan to initiate a global confirmatory Phase 3 clinical trial of z-rostudirsen in the second quarter of 2026, and we have aligned with the FDA on the Phase 3 trial design and protocol." https://www.sec.gov/Archives/edgar/data/1818794/000119312526215702/dyn-20260331.htm
- SEC Form 10-K (accession 0001193125-26-084178): "Further, we plan to initiate a global confirmatory Phase 3 clinical trial of z-rostudirsen in the second quarter of 2026, and we have aligned with the FDA on the Phase 3 trial design and protocol." https://www.sec.gov/Archives/edgar/data/1818794/000119312526084178/dyn-20251231.htm
- SEC prospectus (424B) (accession 0001193125-25-314307): "We plan to initiate a global Phase 3 clinical trial of z-rostudirsen in the second quarter of 2026 to support global approvals." https://www.sec.gov/Archives/edgar/data/1818794/000119312525314307/d72555d424b5.htm

### Q2 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-08-04, last confirmed 2026-05-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-215720): "- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 -" https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/dyn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-215720): "Dyne has completed a positive pre-BLA meeting with the U.S. Food and Drug Administration (FDA) and remains on track to submit a Biologics License Application (BLA) for U.S. Accelerated Approval in Q2 2026." https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/dyn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-084207): "Dyne plans to submit a Biologics License Application (BLA) for U.S. Accelerated Approval in Q2 2026." https://www.sec.gov/Archives/edgar/data/1818794/000119312526084207/dyn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101620): "- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 -" https://www.sec.gov/Archives/edgar/data/1818794/000095017025101620/dyn-ex99_1.htm

### May 2026: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2026-07-29, last confirmed 2026-07-29.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-323940): "Dyne initiated the global confirmatory Phase 3 FORZETTO trial of z-rostudirsen in May 2026." https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/dyn-ex99_1.htm

### Jul 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: individuals with DMD amenable to exon 51 skipping.
- First seen 2026-11-05, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001818794-26-000012): "In July 2026, we announced that the FDA accepted for review our BLA for z-rostudirsen for the treatment of individuals with DMD amenable to exon 51 skipping." https://www.sec.gov/Archives/edgar/data/1818794/000181879426000012/dyn-20260930.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001818794-26-000013): ""This includes preparations for the potential U.S. launch of z-rostudirsen for exon 51 DMD, if approved, and topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, both expected in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-ex99_1.htm

### January 21, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-07-20, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001818794-26-000013): "- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -" https://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-323940): "- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -" https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/dyn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001818794-26-000013): "Dyne's BLA is under priority review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of January 21, 2027." https://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-323940): "Dyne's BLA was accepted for review by the FDA in July 2026, with Priority Review granted (Prescription Drug User Fee Act (PDUFA) target action date set for January 21, 2027)." https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/dyn-ex99_1.htm
- SEC Form 8-K (accession 0001193125-26-308343): "The FDA has granted the BLA Priority Review and assigned a Prescription Drug User Fee Act target action date of January 21, 2027." https://www.sec.gov/Archives/edgar/data/1818794/000119312526308343/dyn-20260720.htm
- SEC Form 10-Q (accession 0001818794-26-000012): "The FDA has granted the BLA priority review and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of January 21, 2027." https://www.sec.gov/Archives/edgar/data/1818794/000181879426000012/dyn-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-323639): "The FDA has granted the BLA priority review and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of January 21, 2027." https://www.sec.gov/Archives/edgar/data/1818794/000119312526323639/dyn-20260630.htm
- SEC prospectus (424B) (accession 0001193125-26-312576): "Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 21, 2027." https://www.sec.gov/Archives/edgar/data/1818794/000119312526312576/d98164d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-310573): "Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 21, 2027." https://www.sec.gov/Archives/edgar/data/1818794/000119312526310573/d98164d424b5.htm

Calendar months: [January 2027](https://sec-api.dev/fda-calendar/2027-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/z-rostudirsen.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Z-rostudirsen PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/z-rostudirsen

```bibtex
@misc{secapidev_pdufa_z_rostudirsen_20261116,
  title        = {Z-rostudirsen PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/z-rostudirsen}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_z_rostudirsen_20261116","title":"Z-rostudirsen PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/z-rostudirsen","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
